TrialFuture oncology (London, England)2019

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

Debu Tripathy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.